
## **Christopher Liddle**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9065790/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	β3-Adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity. Journal of Clinical Investigation, 2022, 132, .	3.9	42
2	Obesity alters pathology and treatment response in inflammatory disease. Nature, 2022, 604, 337-342.	13.7	93
3	Daily running enhances molecular and physiological circadian rhythms in skeletal muscle. Molecular Metabolism, 2022, 61, 101504.	3.0	14
4	Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways. Cellular and Molecular Life Sciences, 2021, 78, 1011-1027.	2.4	10
5	An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Letters, 2021, 501, 124-132.	3.2	38
6	Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. Journal of Inflammation Research, 2021, Volume 14, 1257-1270.	1.6	10
7	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 2021, 8, 2004168.	5.6	10
8	Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. Cell Systems, 2021, 12, 432-445.e7.	2.9	12
9	Expression of CYP24A1 and other multiple sclerosis risk genes in peripheral blood indicates response to vitamin D in homeostatic and inflammatory conditions. Genes and Immunity, 2021, 22, 227-233.	2.2	3
10	FGF21 promotes thermogenic gene expression as an autocrine factor in adipocytes. Cell Reports, 2021, 35, 109331.	2.9	55
11	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 2021, 70, 103521.	2.7	11
12	Glycogen metabolism links glucose homeostasis to thermogenesis in adipocytes. Nature, 2021, 599, 296-301.	13.7	36
13	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 2020, 71, 1213-1227.	3.6	209
14	Regulation of the methylome in differentiation from adult stem cells may underpin vitamin D risk in MS. Genes and Immunity, 2020, 21, 335-347.	2.2	2
15	Immune-evasive human islet-like organoids ameliorate diabetes. Nature, 2020, 586, 606-611.	13.7	192
16	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. Breast, 2020, 54, 229-234.	0.9	3
17	Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer. Breast Cancer Research, 2020, 22, 39.	2.2	29
18	Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3. Nature Metabolism, 2020, 2, 620-634.	5.1	25

#	Article	IF	CITATIONS
19	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PLoS ONE, 2020, 15, e0243590.	1.1	3
20	The latitude-dependent autoimmune disease risk genes ZMIZ1 and IRF8 regulate mononuclear phagocytic cell differentiation in response to vitamin D. Human Molecular Genetics, 2019, 28, 269-278.	1.4	5
21	Altered cytochrome 2E1 and 3A P450â€dependent drug metabolism in advanced ovarian cancer correlates to tumourâ€associated inflammation. British Journal of Pharmacology, 2019, 176, 3712-3722.	2.7	14
22	IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 2019, 9, 14834.	1.6	16
23	Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?. Breast, 2019, 46, 52-57.	0.9	9
24	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 2019, 9, 1439.	1.6	7
25	FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell, 2019, 176, 1098-1112.e18.	13.5	291
26	Macrophage Coordination of the Interferon Lambda Immune Response. Frontiers in Immunology, 2019, 10, 2674.	2.2	44
27	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR. Journal of Hepatology, 2019, 70, 494-500.	1.8	67
28	ERRÎ <sup>3</sup> Promotes Angiogenesis, Mitochondrial Biogenesis, and Oxidative Remodeling in PGC1α/β-Deficient Muscle. Cell Reports, 2018, 22, 2521-2529.	2.9	58
29	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	1.8	144
30	Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Advanced Drug Delivery Reviews, 2018, 134, 107-121.	6.6	63
31	ERRÎ <sup>3</sup> Preserves Brown Fat Innate Thermogenic Activity. Cell Reports, 2018, 22, 2849-2859.	2.9	30
32	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67, 2150-2166.	3.6	189
33	Vitamin D Switches BAF Complexes to Protect $\hat{I}^2$ Cells. Cell, 2018, 173, 1135-1149.e15.	13.5	162
34	Overcoming treatment resistance in cancer: Current understanding and tactics. Cancer Letters, 2017, 387, 69-76.	3.2	35
35	Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1129-1134.	3.3	125
36	The membraneâ€bound Oâ€acyltransferase domainâ€containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 2017, 65, 1840-1850.	3.6	74

#	Article	IF	CITATIONS
37	IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis. Nature Genetics, 2017, 49, 795-800.	9.4	86
38	PPARδPromotes Running Endurance by Preserving Glucose. Cell Metabolism, 2017, 25, 1186-1193.e4.	7.2	154
39	NCoR1 restrains thymic negative selection by repressing Bim expression to spare thymocytes undergoing positive selection. Nature Communications, 2017, 8, 959.	5.8	17
40	Circadian clock cryptochrome proteins regulate autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12548-12553.	3.3	84
41	Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12542-12547.	3.3	115
42	Inhibition of IKKÉ› and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metabolism, 2017, 26, 157-170.e7.	7.2	127
43	Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. Cancer Chemotherapy and Pharmacology, 2017, 80, 385-393.	1.1	25
44	Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells. Theranostics, 2017, 7, 3948-3961.	4.6	51
45	Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. PLoS ONE, 2017, 12, e0189051.	1.1	31
46	Aptamers: A promising chemical antibody for cancer therapy. Oncotarget, 2016, 7, 13446-13463.	0.8	82
47	Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation. Cell, 2016, 165, 1644-1657.	13.5	130
48	ERRÎ <sup>3</sup> Is Required for the Metabolic Maturation of Therapeutically Functional Glucose-Responsive βÂCells. Cell Metabolism, 2016, 23, 622-634.	7.2	139
49	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. Clinical Cancer Research, 2016, 22, 3164-3171.	3.2	60
50	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 2016, 7, 12757.	5.8	104
51	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 2016, 64, 34-46.	3.6	83
52	FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 2016, 64, 390-398.	1.8	64
53	Antimicrobials in Cirrhotic Patients AfterÂUpper Gastrointestinal Hemorrhage: One Size No Longer Fits All. Clinical Gastroenterology and Hepatology, 2016, 14, 324-325.	2.4	1
54	Coherence analysis discriminates between retroviral integration patterns in CD34+ cells transduced under differing clinical trial conditions. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15015.	1.8	1

#	Article	IF	CITATIONS
55	Hepatocyte- Specific Deletion of ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) Results in Altered Fibrotic Gene Expression in the Thioacetamide Model of Liver Injury. PLoS ONE, 2015, 10, e0121650.	1.1	8
56	BRD4 is a novel therapeutic target for liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15713-15718.	3.3	171
57	Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine, 2015, 21, 159-165.	15.2	562
58	A subcutaneous adipose tissue–liver signalling axis controls hepatic gluconeogenesis. Nature Communications, 2015, 6, 6047.	5.8	75
59	High-fat diet and FGF21 cooperatively promote aerobic thermogenesis in mtDNA mutator mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8714-8719.	3.3	47
60	Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422.	5.8	156
61	ERRs Mediate a Metabolic Switch Required for Somatic Cell Reprogramming to Pluripotency. Cell Stem Cell, 2015, 16, 547-555.	5.2	109
62	Dependence of Hippocampal Function on ERRÎ <sup>3</sup> -Regulated Mitochondrial Metabolism. Cell Metabolism, 2015, 21, 628-636.	7.2	45
63	Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 1509-1519.	1.5	42
64	Depletion of fat-resident Treg cells prevents age-associated insulin resistance. Nature, 2015, 528, 137-141.	13.7	261
65	Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a safe and effective strategy?. Journal of Clinical Oncology, 2015, 33, 557-557.	0.8	Ο
66	Binding Sites Analyser (BiSA): Software for Genomic Binding Sites Archiving and Overlap Analysis. PLoS ONE, 2014, 9, e87301.	1.1	11
67	Impact of Parenteral Nutrition Versus Fasting on Hepatic Bile Acid Production and Transport in a Rabbit Model of Prolonged Critical Illness. Shock, 2014, 41, 48-54.	1.0	16
68	Barx2 and Pax7 Have Antagonistic Functions in Regulation of Wnt Signaling and Satellite Cell Differentiation. Stem Cells, 2014, 32, 1661-1673.	1.4	27
69	The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells. Human Molecular Genetics, 2014, 23, 1425-1434.	1.4	40
70	IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 2014, 20, 598-605.	1.1	15
71	Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. Multiple Sclerosis Journal, 2014, 20, 675-685.	1.4	23
72	Withholding parenteral nutrition during critical illness increases plasma bilirubin but lowers the incidence of biliary sludge. Hepatology, 2014, 60, 202-210.	3.6	28

#	Article	IF	CITATIONS
73	Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell, 2014, 159, 80-93.	13.5	871
74	Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature, 2014, 513, 436-439.	13.7	201
75	Metabolic Crosstalk: Molecular Links Between Glycogen and Lipid Metabolism in Obesity. Diabetes, 2014, 63, 2935-2948.	0.3	69
76	Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC) Journal of Clinical Oncology, 2014, 32, 2597-2597.	0.8	3
77	Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research, 2013, 30, 2270-2278.	1.7	14
78	An inhibitor of the protein kinases TBK1 and IKK-É> improves obesity-related metabolic dysfunctions in mice. Nature Medicine, 2013, 19, 313-321.	15.2	364
79	Insights into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of Inflammatory Cistromes. Molecular Cell, 2013, 49, 158-171.	4.5	233
80	A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response. Cell, 2013, 153, 601-613.	13.5	513
81	PPARÎ <sup>3</sup> signaling and metabolism: the good, the bad and the future. Nature Medicine, 2013, 19, 557-566.	15.2	1,526
82	Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?. Hepatology, 2013, 57, 2180-2188.	3.6	136
83	Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease?. Expert Review of Clinical Pharmacology, 2013, 6, 597-599.	1.3	19
84	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation Journal of Clinical Oncology, 2013, 31, 543-543.	0.8	26
85	Metformin-Mediated Bambi Expression in Hepatic Stellate Cells Induces Prosurvival Wnt/β-Catenin Signaling. Cancer Prevention Research, 2012, 5, 553-561.	0.7	33
86	FXR and PXR: Potential therapeutic targets in cholestasis. Journal of Steroid Biochemistry and Molecular Biology, 2012, 130, 147-158.	1.2	127
87	Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature, 2012, 485, 123-127.	13.7	867
88	Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology, 2011, 54, 1741-1752.	3.6	86
89	Extrahepatic Cancer Suppresses Nuclear Receptor–Regulated Drug Metabolism. Clinical Cancer Research, 2011, 17, 3170-3180.	3.2	31
90	FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways. PLoS ONE, 2011, 6, e17868.	1.1	135

#	Article	IF	CITATIONS
91	Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 331-337.	1.0	90
92	Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 137-149.	1.5	80
93	Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. Molecular Pharmaceutics, 2008, 5, 49-59.	2.3	67
94	Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients. Clinical Cancer Research, 2008, 14, 817-825.	3.2	90
95	Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer. Clinical Cancer Research, 2006, 12, 7492-7497.	3.2	76
96	Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11323-11328.	3.3	157
97	Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney International, 2005, 68, 2599-2607.	2.6	45
98	Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2063-2068.	3.3	208
99	Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2198-2203.	3.3	84
100	Feed-forward Regulation of Bile Acid Detoxification by CYP3A4. Journal of Biological Chemistry, 2004, 279, 11336-11343.	1.6	84
101	Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology, 2004, 39, 1239-1247.	3.6	175
102	CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy*1. Clinical Pharmacology and Therapeutics, 2004, 75, 529-538.	2.3	86
103	Transgenic Mouse Models of Human CYP3A4 Gene Regulation. Molecular Pharmacology, 2003, 64, 42-50.	1.0	63
104	Changes in Antipyrine Clearance and Platelet Count, But Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 2003, 98, 1384-1390.	0.2	24
105	Predicting inductive drug–drug interactions. Pharmacogenomics, 2003, 4, 141-152.	0.6	14
106	Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. American Journal of Gastroenterology, 2002, 97, 1003-1009.	0.2	20
107	Regulation of Hepatic Drug Metabolism: Role of the Nuclear Receptors PXR and CAR. Seminars in Liver Disease, 2002, 22, 115-122.	1.8	50
108	Transcriptional Regulation of the HumanCYP3A4Gene by the Constitutive Androstane Receptor. Molecular Pharmacology, 2002, 62, 359-365.	1.0	232

#	Article	IF	CITATIONS
109	Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 873-881.	1.4	151
110	NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373-379.	3.6	967
111	HFE mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology, 2002, 36, 142-149.	3.6	214
112	Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?. Hepatology, 2002, 36, 403-409.	3.6	295
113	Drugs and the liver updated, 2002. Seminars in Liver Disease, 2002, 22, 109-13.	1.8	7
114	Incorrect diagnosis of hereditary hemochromatosis. , 2000, 63, 104-105.		1
115	Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands. Journal of Biological Chemistry, 2000, 275, 15122-15127.	1.6	735
116	The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of <i>CYP3A4</i> by Rifampicin through a Distal Enhancer Module. Molecular Pharmacology, 1999, 56, 1329-1339.	1.0	607
117	How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C?. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 419-426.	1.4	27
118	Effects of hepatitis G virus coinfection on severity of hepatitis C: Relationship to risk factors and response to interferon treatment. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 773-780.	1.4	9
119	Culture and transfection of mammalian primary hepatocytes and hepatocyte-derived cell lines. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 855-858.	1.4	4
120	Molecular epidemiology of hepatitis C in Australia. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 914-920.	1.4	34
121	Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998, 27, 128-133.	3.6	573
122	Effects of bile duct ligation on hepatic expression of female-specificCYP2C12 in male and female rats. Hepatology, 1998, 28, 624-630.	3.6	26
123	Sexually Dimorphic Expression of Rat CYP3A9 and CYP3A18 Genes Is Regulated by Growth Hormone. Biochemical and Biophysical Research Communications, 1998, 242, 57-60.	1.0	51
124	Time-dependent expression of cytochrome p450 genes in primary cultures of well-differentiated human hepatocytes. Translational Research, 1997, 129, 638-648.	2.4	40
125	Effects of metyrapone on expression of CYPs 2C11, 3A2, and other 3A genes in rat hepatocytes cultured on matrigel. Biochemical Pharmacology, 1996, 52, 219-227.	2.0	9
126	Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct–ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis. Hepatology, 1995, 22, 580-587.	3.6	37

#	Article	IF	CITATIONS
127	Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology, 1995, 22, 1065-1071.	3.6	19
128	Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochemical Pharmacology, 1995, 49, 873-881.	2.0	94
129	Alpha-interferon 2b in the treatment of chronic hepatitis C: interim report of the first multicentre Australian trial. Gastroenterologia Japonica, 1993, 28, 101-103.	0.4	5
130	Role of the oestrogen receptor in liver regeneration in the male rat. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 524-529.	1.4	12
131	Growth hormone regulation of hepatic cytochrome P450 expression in the rat. Advances in Enzyme Regulation, 1992, 32, 255-263.	2.9	37
132	Constitutive expression and hormonal regulation of male sexually differentiated cytochromes P450 in primary cultured rat hepatocytes. Archives of Biochemistry and Biophysics, 1992, 298, 159-166.	1.4	53
133	The effects of partial hepatectomy on serum sex steroids in humans. Hepatology, 1992, 15, 623-628.	3.6	7
134	The A, B, C, D and E of viral hepatitis: new agents for old diseases. Australian and New Zealand Journal of Medicine, 1990, 20, 3-5.	0.5	4
135	Does hepatitis C virus play a role in "nonâ€viral―chronic liver disease?. Medical Journal of Australia, 1990, 153, 265-271.	0.8	11